Last reviewed · How we verify
XELOX RT
XELOX RT is a combination chemotherapy regimen with radiotherapy that uses capecitabine and oxaliplatin to inhibit DNA synthesis and repair while concurrent radiation damages tumor cells.
XELOX RT is a combination chemotherapy regimen with radiotherapy that uses capecitabine and oxaliplatin to inhibit DNA synthesis and repair while concurrent radiation damages tumor cells. Used for Locally advanced rectal cancer (neoadjuvant setting with radiotherapy).
At a glance
| Generic name | XELOX RT |
|---|---|
| Sponsor | Catholic University of the Sacred Heart |
| Drug class | Combination chemotherapy with radiotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
XELOX (capecitabine + oxaliplatin) is a standard chemotherapy doublet where capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, while oxaliplatin is a platinum agent that forms DNA crosslinks. When combined with radiotherapy (RT), the chemotherapy acts as a radiosensitizer to enhance tumor cell killing through multiple mechanisms of DNA damage.
Approved indications
- Locally advanced rectal cancer (neoadjuvant setting with radiotherapy)
Common side effects
- Diarrhea
- Nausea/vomiting
- Hand-foot syndrome
- Neutropenia
- Mucositis
- Fatigue
Key clinical trials
- Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases (PHASE2)
- Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. (PHASE2, PHASE3)
- Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait (NA)
- Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer (PHASE2)
- Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer (PHASE1)
- Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy (PHASE3)
- Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer (PHASE1)
- Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |